Overview

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
Phase:
Phase 2
Details
Lead Sponsor:
Fougera Pharmaceuticals Inc.